The importance of controlling uterine IGF bioactivity has been demonstrated in the human uterus where low levels of IGFBP-6 and higher levels of IGF-II are associated with uterine leiomyomas (fibroids), compared with normal endometrium [64]. The gene discussed is IGF2; the disease is uterine corpus leiomyoma.